WO2025153000 - ANTI-MASP2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/153000
Publication Date
24.07.2025
International Application No.
PCT/CN2025/072651
International Filing Date
16.01.2025
Title **
[English]
ANTI-MASP2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT AND USE THEREOF
[French]
ANTICORPS ANTI-MASP2 OU FRAGMENT DE LIAISON À L'ANTIGÈNE DE CELUI-CI ET SON UTILISATION
[Chinese]
一种抗MASP2抗体或其抗原结合片段及用途
Applicants **
SALUBRIS (CHENGDU) BIOTECH CO., LTD.
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD
Inventors
MOU, Zongchun
WEI, Wen
ZHANG, Peng
Priority Data
202410069597.9
17.01.2024
CN
202410705582.7
31.05.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1899 | |
| EPO | Filing, Examination, Granting | 13740 | |
| Japan | Filing, Examination, Granting | 2279 | |
| South Korea | Filing, Examination, Granting | 2436 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
25,094
Contact Us
Abstract[English]
The present invention provides an anti-MASP2 antibody and an antigen-binding fragment thereof, and further provides a polynucleotide encoding the antibody, a vector and a host cell for expressing the antibody, a pharmaceutical composition comprising the antibody, and a method and a pharmaceutical use of the antibody for treating MASP2-related diseases.[French]
La présente invention concerne un anticorps anti-MASP2 et un fragment de liaison à l'antigène de celui-ci, et concerne en outre un polynucléotide codant pour l'anticorps, un vecteur et une cellule hôte pour exprimer l'anticorps, une composition pharmaceutique comprenant l'anticorps, et un procédé et une utilisation pharmaceutique de l'anticorps pour le traitement de maladies associées à MASP2.[Chinese]
本发明提供了一种抗MASP2抗体及其抗原结合片段，还提供了编码所述抗体的多核苷酸，用于表达所述抗体的载体和宿主细胞，包含所述抗体的药物组合物，以及所述抗体用于治疗与MASP2相关的疾病的方法和制药用途。